- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01815359
Chimiothérapie intrapéritonéale post-opératoire (EPIC) et chimiothérapie intrapéritonéale hyperthermique (CHIP) d'ICARuS après chirurgie cytoréductive optimale (CRS) pour les néoplasmes de l'appendice, du côlon ou du rectum avec métastases péritonéales isolées (ICARuS)
ICARuS (chimiothérapie intrapéritonéale après chirurgie cytoréductive) : un essai multicentrique randomisé de phase II sur la chimiothérapie intrapéritonéale postopératoire précoce (EPIC) et la chimiothérapie intrapéritonéale hyperthermique (HIPEC) après une chirurgie cytoréductive optimale (CRS) pour les néoplasmes de l'appendice, du côlon ou Rectum avec métastase péritonéale isolée
This is the first randomized trial comparing Early post-operative intraperitoneal chemotherapy (EPIC) and hyperthermic intraperitoneal chemotherapy (HIPEC) for appendiceal and colorectal cancer. The purpose of this study is to find out what effects, good and/or bad, EPIC and HIPEC after cytoreductive surgery have on the patient and the appendiceal, rectal or colon cancer.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
Florida
-
Miami, Florida, États-Unis
- University of Miami
-
-
Missouri
-
St Louis, Missouri, États-Unis, 63110
- Washington University School of Medicine
-
-
New Jersey
-
Basking Ridge, New Jersey, États-Unis, 07920
- Memorial Sloan Kettering Basking Ridge (Consent and Follow up)
-
Middletown, New Jersey, États-Unis, 07748
- Memorial Sloan Kettering Monmouth (Consent and Follow up)
-
Montvale, New Jersey, États-Unis, 07645
- Memorial Sloan Kettering Bergen (Consent and Follow up)
-
-
New York
-
Commack, New York, États-Unis, 11725
- Memorial Sloan Kettering Commack (Consent and Follow up)
-
Harrison, New York, États-Unis, 10604
- Memorial Sloan Kettering Westchester (Consent and Follow up)
-
New York, New York, États-Unis, 10065
- Memorial Sloan Kettering Cancer Center
-
Uniondale, New York, États-Unis, 11553
- Memorial Sloan Kettering Nassau (Consent and Follow up)
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Patient's age 18 years or older, both genders.
- Clinical diagnosis of appendiceal or colorectal neoplasm with peritoneal mucinosis or metastasis.
- Patient must be planning to undergo complete cytoreduction of all peritoneal disease.
- ECOG performance status ≤ 1.
- Hematology: ANC ≥ 1,500/ μL; Platelets > 75,000/ μL.
- Adequate Renal function Creatinine <1.5 x the upper limit of normal (ULN) or calculated creatinine clearance of ≥ 50ml/min.
- Adequate Hepatic function: Bilirubin less than 1.5mg/dL; (except in patients with Gilbert's Syndrome, who must have a total bilirubin less than 3.0mg/dL).
- Women with childbearing potential who are negative for pregnancy test (urine or blood) and who agree to use effective contraceptive method. Reliable contraception should be used from trial screening and must be continued throughout the study. A woman of childbearing potential is defined as one who is biologically capable of becoming pregnant.
- A man participating in this study must agree to utilize reliable barrier form of contraception for the duration of the study.
- Signed and dated written informed consent to participate in this clinical trial must be obtained prior to any study procedure.
- Subjects with a history of endometrial cancer are eligible only if they presented with a stage lower than 1A and if the histology was a subtype other than poorly differentiated.
Exclusion Criteria:
- Subjects who have previously undergone intraperitoneal chemotherapy.
- Subjects with classical carcinoid
- Tumors of low malignant potential
- Other prior malignancies, except for cured non-melanoma skin cancer, curatively treated in situ carcinoma of the cervix, adequately treated malignancies for which there has been no evidence of activity for more than 3 years or indolent tumors for which observation over three years is a reasonable option.
- Presence of clinically apparent or suspected metastasis to sites other than lymph nodes or peritoneal surfaces.
- Women who are pregnant or lactating.
- Subjects with a condition which may interfere with the subjects' ability to understand the requirements of the study.
- Active coronary artery disease (defined as unstable angina or a positive cardiac stress test).
- Subjects with a history of coronary artery disease may be included if they have had a normal stress test within 60 days of enrollment and/or were cleared by MSK cardiology.
- Uncontrolled hypertension defined as >140/90 and not cleared for surgery at the time of consent.
- New York Heart Association (NYHA) Class II or higher Congestive heart failure.
- Restrictive or obstructive pulmonary disease that would limit study compliance or place the patient at unacceptable risk for participation in the study.
- History of cerebrovascular disease. that would limit study compliance or place the patient at unacceptable risk for participation in the study.
- Subjects with other concurrent severe medical problems unrelated to the malignancy that would significantly limit full compliance with the study or places them at an unacceptable risk for participation in the study.
- Patients with known floxuridine, leucovorin ,or mitomycin allergy.
- Evidence of extensive intraperitoneal adhesions at the time of surgery which prohibits intraperitoneal therapy, as determined by the operating surgeon.
- Any condition that would preclude the ability to deliver appropriate IP therapy.
- Use of an oral medication, lacking a suitable non-oral substitute, that if held for up to ten days, would be felt an unacceptable risk by the investigator.
- Life expectancy < 12 weeks.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Appendiceal, no chemotherapy within 6 months prior to surgery
First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the PI or Co-PI.
|
Optimal Surgical Debulking |
|
Expérimental: Appendiceal, chemotherapy within 6 months prior to surgery
First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the PI or Co-PI.
|
Optimal Surgical Debulking |
|
Expérimental: Colorectal, no chemotherapy within 6 months prior to surgery
First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the PI or Co-PI.
|
Optimal Surgical Debulking |
|
Expérimental: Colorectal, chemotherapy within 6 months prior to surgery
First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the PI or Co-PI.
|
Optimal Surgical Debulking |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
disease-free survival
Délai: 3 years
|
Documentation of tumor recurrence will be made based on surveillance CT/PET CT scans at time points as determined by attending radiologist, with clinical correlation from the treating physician. |
3 years
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
surgical toxicity grade 3 to 5
Délai: up to 60 days
|
We will evaluate toxicity up to 30 days postoperatively for any surgical Grade 3-5 complications/toxicites or chemotherapy related Grade 4 or 5 toxicities. Surgical morbidity will be graded using the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 |
up to 60 days
|
|
chemotherapy toxicity grade 3 to 5
Délai: up to 60 days
|
We will evaluate toxicity up to 30 days postoperatively for any surgical Grade 3-5 complications/toxicities or chemotherapy related Grade 4 or 5 toxicities. |
up to 60 days
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Garrett Nash, MD, MPH, Memorial Sloan Kettering Cancer Center
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimé)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Tumeurs par site
- Tumeurs
- Maladies intestinales
- Tumeurs gastro-intestinales
- Tumeurs du système digestif
- Maladies du système digestif
- Maladies gastro-intestinales
- Tumeurs intestinales
- Maladies rectales
- Maladies du côlon
- Tumeurs cæcales
- Maladies cæcales
- Tumeurs colorectales
- Tumeurs appendiculaires
- Produits chimiques organiques
- Composés hétérocycliques, 1 anneau
- Composés hétérocycliques
- Composés hétérocycliques, 2 anneaux
- Composés hétérocycliques, anneau fusionné
- Thérapeutique
- Procédures chirurgicales, opératoires
- Pharmacothérapie
- Acides nucléiques, nucléotides et nucléosides
- Enzymes et coenzymes
- Indoles
- Nucléosides pyrimidine
- Pyrimidines
- Nucléosides
- Formyltétrahydrofolate
- Tétrahydrofolat
- Acide folique
- Pterines
- Ptéridines
- Hyperthermie, induite
- Coenzymes
- Quinones
- Azirines
- Désoxyribonucléosides
- Thérapie de modalité combinée
- Désoxyuridine
- Uridine
- Mitomycines
- Indoléquinones
- Chimiothérapie, adjuvant
- Leucovorine
- Mitomycine
- Floxuridine
- Procédures chirurgicales de cytoréduction
- Chimiothérapie intrapéritonéale hyperthermique
Autres numéros d'identification d'étude
- 12-289
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .